Sensorineural Hearing Loss Clinical Trials | A Drug Pipeline Analysis Report 2024 | Sensorion, AudioCure Pharma, Audion Therapeutics, Reyon Pharmaceutical, Decibel Therapeutics, Sound Pharmaceuticals, Otonomy, Pipeline Therapeutics, Heyu (Suzhou) Pharmace

DelveInsight's 'Sensorineural Hearing Loss Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Sensorineural Hearing Loss therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Sensorineural Hearing Loss pipeline domain.
Request for a sample report @ https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Sensorineural Hearing Loss Pipeline Report
Over 21+ Sensorineural Hearing Loss pipeline therapies are in various stages of development, and their anticipated acceptance in the Sensorineural Hearing Loss market would significantly increase market revenue.
Leading Sensorineural Hearing Loss companies developing novel drug candidates to improve the Sensorineural Hearing Loss treatment landscape include Pipeline Therapeutics, Audion Therapeutics, Otonomy, and others.
Promising Sensorineural Hearing Loss pipeline therapies in various stages of development include PIPE 505, LY 3056480, OTO 413, and others.
Sensorineural Hearing Loss Overview
Sensorineural Hearing Loss (SHL) is caused by damage to the structures in your inner ear or your auditory nerve. It is responsible for more than 90 percent of hearing loss in adults. Common causes of SHL include exposure to loud noises, genetic factors, or the natural aging process. Individuals with SHL may experience difficulties in understanding speech, hearing faint sounds, or distinguishing between different sounds. Diagnosis typically involves a comprehensive hearing evaluation by an audiologist, which may include a physical examination, hearing tests, and imaging studies.

SHL is characterized by various signs and symptoms that can impact an individual's auditory experience. Common indicators of SHL include difficulty understanding speech, muffled hearing, a sensation of fullness in the ear, and a gradual or sudden loss of hearing. Additionally, individuals with SHL may struggle to follow conversations in noisy environments, experience a ringing or buzzing sound in the ears (tinnitus), find it challenging to differentiate between high-pitched sounds, and perceive voices as mumbled or slurred.

Currently, there is no surgical option to treat SHL. The most common treatment options are hearing aids and cochlear implants, which help compensate for hearing loss. Gene therapy for hearing loss is an expanding field of research, but it is not yet clinically used for SHL.
Download our report to know more about the pipeline segment @ https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Sensorineural Hearing Loss Emerging Drugs

SENS-401: Sensorion
SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss (SSNHL). It is aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss. It is protected by a solid intellectual property with two patent families. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with Sensorineural Hearing Loss.

AC-102: AudioCure Pharma
AC-102 is a disease modifying novel molecule. Preclinical models have demonstrated the unique potential of AC102 to act beneficially upon three cell types of the inner ear which are critical for the hearing process: the sensory inner hair cells, the sensory outer hair cells and the acoustic nerve. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Sensorineural Hearing Loss (SHL).

LY 3056480: Audion Therapeutics
Audion's lead candidate (LY 3056480) has undergone a thorough and extensive preclinical characterization in multiple model systems prior to initiation of the clinical studies. These studies include effects of the drug on damaged inner ear tissue, inner ear PK studies to determine drug exposure using different formulations and formal ototoxicity studies to exclude toxic effects on normal hair cells and inner ear tissues. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Sensorineural Hearing Loss (SHL).

Discover more about the emerging Sensorineural Hearing Loss drugs @ https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Sensorineural Hearing Loss Key Companies
Pipeline Therapeutics
Audion Therapeutics
Otonomy
Sensorineural Hearing Loss Pipeline Therapies
PIPE 505
LY 3056480
OTO 413
Sensorineural Hearing Loss Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Sensorineural Hearing Loss Pipeline Report
Coverage: Global
Key Sensorineural Hearing Loss Companies: Pipeline Therapeutics, Audion Therapeutics, Otonomy, and others
Key Sensorineural Hearing Loss Pipeline Therapies: PIPE 505, LY 3056480, OTO 413, and others
Find out more about the Sensorineural Hearing Loss treatment options in development @ https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.